EU/3/14/1344: Orphan designation for the treatment of cystic fibrosis

Nitric oxide

Overview

On 15 October 2014, orphan designation (EU/3/14/1344) was granted by the European Commission to PD Dr med. Joachim Riethmüller, Germany, for nitric oxide for the treatment of cystic fibrosis.

Key facts

Active substance
Nitric oxide
Intented use
Treatment of cystic fibrosis
Orphan designation status
Positive
EU designation number
EU/3/14/1344
Date of designation
15/10/2014
Sponsor
PD Dr med. Joachim Riethmüller
Beethovenweg 7
72076 Tübingen
Germany
Tel. +49 7071 298 1442
Fax +49 7071 294 450
E-mail: joachim.riethmueller@med.uni-tuebingen.de

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating